CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
Frequently asked questions
What sector does Cannabics Pharmaceuticals Inc (CNBX) operate in?
Cannabics Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cannabics Pharmaceuticals Inc (CNBX) current stock price?
As of the latest data, Cannabics Pharmaceuticals Inc stock price is $0.00, with a previous close of $0.00.
What is Cannabics Pharmaceuticals Inc (CNBX) current market capitalization?
Cannabics Pharmaceuticals Inc market cap is approximately 321.15 thousand.
What is Cannabics Pharmaceuticals Inc (CNBX) EBITDA?
Cannabics Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -162.76 thousand.
Does Cannabics Pharmaceuticals Inc (CNBX) pay dividends?
No. Cannabics Pharmaceuticals Inc does not pay a dividend.
What is Cannabics Pharmaceuticals Inc (CNBX) beta (volatility) score?
Cannabics Pharmaceuticals Inc has a beta of 0.698, indicating lower volatility than the overall market.
